title: Comparison of cardiac function tests after anthracycline therapy in childhood. Implications for screening.
abstract: BACKGROUND
  Numerous methods for evaluating cardiac function after cardiotoxic therapy have been suggested. A practical algorithm for screening a large patient population is needed.
  
  
  METHODS
  Seventy-three patients (median age, 15.3 years [range, 9-29 years) who received anthracyclines (median dose, 300 mg/m2 [range, 50-750 mg/m2) for a childhood malignancy underwent a battery of commonly used tests of cardiac function: (1) echocardiographic shortening fraction (ESF); (2) resting and exercise radionuclide scan (multiple gaited acquisition [MUGA]); (3) electrocardiogram (ECG); (4) 24-hour Holter monitor, and (5) questionnaire concerning exercise tolerance.
  
  
  RESULTS
  Patients with an abnormal resting ejection fraction on MUGA were more likely to have an abnormal ESF (P = 0.023), prolongation of the QTc interval (P = 0.014), and complaints of "difficulty" with exercise (P = 0.04). An abnormal results for a resting study was not predictive of an abnormal MUGA exercise response. There was no association between the presence of significant dysrhythmia on Holter monitor and any resting test. An algorithm was developed using a normal ESF and QTc interval, and a negative history of exercise intolerance to identify patients who need not undergo a MUGA. With the use of such an algorithm, 29 of the 73 patients would not have undergone the MUGA, only 2 of whom had an abnormal resting ejection fraction.
  
  
  CONCLUSIONS
  Patients at risk for cardiac damage after cancer therapy who have normal ESF and QTc interval results and no history of exercise intolerance are unlikely to have abnormal MUGA results. Significant dysrhythmia may be present in the absence of other abnormalities.
authors.affiliation: Division of Oncology, Children's Hospital of Philadelphia, PA 19104.
authors.forename: R I
authors.initials: RI
authors.lastname: Jakacki
authors.forename: R L
authors.initials: RL
authors.lastname: Larsen
authors.forename: G
authors.initials: G
authors.lastname: Barber
authors.forename: S
authors.initials: S
authors.lastname: Heyman
authors.forename: M
authors.initials: M
authors.lastname: Fridman
authors.forename: J H
authors.initials: JH
authors.lastname: Silber
mesh_terms: D000293:Adolescent; D000328:Adult; D000903:Antibiotics, Antineoplastic / Q000009:adverse effects* / Q000627:therapeutic use; D002648:Child; D004452:Echocardiography; D004562:Electrocardiography; D015716:Electrocardiography, Ambulatory; D015637:Gated Blood-Pool Imaging; D006321:Heart / Q000187:drug effects; D006331:Heart Diseases / Q000139:chemically induced* / Q000175:diagnosis*; D006334:Heart Function Tests; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000503:physiopathology; D005082:Physical Exertion
chemical_list: D000903:Antibiotics, Antineoplastic